CN110023327B - 在具有改善光敏感性的通道视蛋白变体中突变的识别及其使用方法 - Google Patents

在具有改善光敏感性的通道视蛋白变体中突变的识别及其使用方法 Download PDF

Info

Publication number
CN110023327B
CN110023327B CN201780060143.3A CN201780060143A CN110023327B CN 110023327 B CN110023327 B CN 110023327B CN 201780060143 A CN201780060143 A CN 201780060143A CN 110023327 B CN110023327 B CN 110023327B
Authority
CN
China
Prior art keywords
cell
val
vector
leu
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780060143.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN110023327A (zh
Inventor
Z-H·潘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Original Assignee
Wayne State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University filed Critical Wayne State University
Priority to CN202410173021.7A priority Critical patent/CN119979612A/zh
Publication of CN110023327A publication Critical patent/CN110023327A/zh
Application granted granted Critical
Publication of CN110023327B publication Critical patent/CN110023327B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780060143.3A 2016-08-29 2017-08-29 在具有改善光敏感性的通道视蛋白变体中突变的识别及其使用方法 Active CN110023327B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410173021.7A CN119979612A (zh) 2016-08-29 2017-08-29 在具有改善光敏感性的通道视蛋白变体中突变的识别及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380871P 2016-08-29 2016-08-29
US62/380,871 2016-08-29
PCT/US2017/049158 WO2018044912A1 (en) 2016-08-29 2017-08-29 Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410173021.7A Division CN119979612A (zh) 2016-08-29 2017-08-29 在具有改善光敏感性的通道视蛋白变体中突变的识别及其使用方法

Publications (2)

Publication Number Publication Date
CN110023327A CN110023327A (zh) 2019-07-16
CN110023327B true CN110023327B (zh) 2024-02-27

Family

ID=59859616

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780060143.3A Active CN110023327B (zh) 2016-08-29 2017-08-29 在具有改善光敏感性的通道视蛋白变体中突变的识别及其使用方法
CN202410173021.7A Pending CN119979612A (zh) 2016-08-29 2017-08-29 在具有改善光敏感性的通道视蛋白变体中突变的识别及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410173021.7A Pending CN119979612A (zh) 2016-08-29 2017-08-29 在具有改善光敏感性的通道视蛋白变体中突变的识别及其使用方法

Country Status (15)

Country Link
US (3) US11041004B2 (https=)
EP (1) EP3504227A1 (https=)
JP (1) JP7116884B2 (https=)
KR (3) KR102609571B1 (https=)
CN (2) CN110023327B (https=)
AU (4) AU2017319306B2 (https=)
BR (1) BR112019003950A2 (https=)
CA (1) CA3034887A1 (https=)
IL (2) IL265010B2 (https=)
MX (1) MX2019002321A (https=)
MY (1) MY197491A (https=)
NZ (1) NZ751983A (https=)
RU (1) RU2019109021A (https=)
SG (2) SG10202102061SA (https=)
WO (1) WO2018044912A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3504227A1 (en) 2016-08-29 2019-07-03 Wayne State University Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
CN113173984B (zh) 2021-04-12 2022-08-30 中眸医疗科技(武汉)有限公司 一种新型光敏感通道蛋白vr1.0在制备视网膜感光细胞退行性疾病药物中的应用
MX2024007770A (es) * 2021-12-20 2024-07-01 Genans Biotechnology Co Ltd Restauracion visual optogenetica utilizando neuropsina acoplada a gq sensible a la luz (opsin 5).
EP4665750A1 (en) 2023-02-17 2025-12-24 Ray Therapeutics, Inc. Gene therapy compositions and methods for treating diseases of the retina
WO2025137649A1 (en) * 2023-12-22 2025-06-26 Wayne State University Method of enhancing viral mediated gene delivery

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104334575A (zh) * 2012-03-05 2015-02-04 韦恩州立大学 通道视蛋白-2(Chop2)突变的鉴定及使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IE913929A1 (en) 1990-11-13 1992-05-20 Immunex Corp Bifunctional selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
EP1919497B1 (en) 2005-07-22 2020-02-12 The Board of Trustees of the Leland Stanford Junior University Light-activated cation channel and uses thereof
CN101484005A (zh) 2006-05-04 2009-07-15 韦恩州立大学 通过向体内递送视紫红质核酸恢复视觉响应
KR100922422B1 (ko) 2006-06-27 2009-10-16 가부시키가이샤 어드밴테스트 반도체 시험 장치 및 반도체 메모리의 시험 방법
WO2011140279A1 (en) 2010-05-04 2011-11-10 Wayne State University Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
KR101945962B1 (ko) 2010-09-08 2019-02-08 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 돌연변이 채널로돕신 2
CN105755044A (zh) 2011-04-22 2016-07-13 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
WO2013071231A1 (en) * 2011-11-12 2013-05-16 Massachusetts Institute Of Technology Channelrhodopsins for optical control of cells
EP2968476B1 (en) * 2013-03-14 2021-05-05 Wayne State University A plasmin for use in enhancing delivery of therapeutic compounds to the eyes or for improving vision
EP3102290A1 (en) * 2014-02-07 2016-12-14 Massachusetts Institute Of Technology Blue light-activated ion channel molecules and uses thereof
EP4678754A3 (en) 2014-03-11 2026-04-08 Wayne State University A modified mglur6 promoter and methods of use
WO2015161308A1 (en) 2014-04-18 2015-10-22 Massachusetts Institute Of Technology Mutant channelrhodopsins with altered ion selectivity
WO2016179038A1 (en) 2015-05-01 2016-11-10 Spark Therapeutics, Inc. ADENO-ASSOCIATED VIRUS-MEDIATED CRISPR-Cas9 TREATMENT OF OCULAR DISEASE
LT3436051T (lt) 2016-03-31 2021-11-25 Spark Therapeutics, Inc. Kolonėlėmis pagrįstas visiškai keičiamo masto raav gavimo būdas
WO2017210664A1 (en) 2016-06-03 2017-12-07 Massachusetts Institute Of Technology Somatic opsins for single cell resolution optogenetics
AU2017302013B2 (en) 2016-07-29 2022-05-26 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
EP3504227A1 (en) 2016-08-29 2019-07-03 Wayne State University Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104334575A (zh) * 2012-03-05 2015-02-04 韦恩州立大学 通道视蛋白-2(Chop2)突变的鉴定及使用方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Kenji Sakagami et al..Physiology of rat retinal pericytes: modulation of ion channel activity by serum-derived molecules.《J Physiol》.1999,第637-650页. *
Physiology of rat retinal pericytes: modulation of ion channel activity by serum-derived molecules;Kenji Sakagami et al.;《J Physiol》;19991215;第637-650页 *
丁宁等.体外培养视网膜神经元电压门控钾离子通道特性的研究.《首都医科大学学报》.2007,第28卷(第2期),第239-242页. *
体外培养视网膜神经元电压门控钾离子通道特性的研究;丁宁等;《首都医科大学学报》;20070430;第28卷(第2期);第239-242页 *

Also Published As

Publication number Publication date
IL265010B1 (en) 2024-02-01
SG11201901697QA (en) 2019-03-28
JP7116884B2 (ja) 2022-08-12
US11041004B2 (en) 2021-06-22
RU2019109021A (ru) 2020-09-29
WO2018044912A1 (en) 2018-03-08
KR102609571B9 (ko) 2025-11-20
IL310142A (en) 2024-03-01
EP3504227A1 (en) 2019-07-03
JP2019528781A (ja) 2019-10-17
AU2024200016B2 (en) 2025-07-17
AU2024200016A1 (en) 2024-01-25
BR112019003950A2 (pt) 2019-06-25
CA3034887A1 (en) 2018-03-08
KR20250159068A (ko) 2025-11-07
US20250163111A1 (en) 2025-05-22
US12234267B2 (en) 2025-02-25
KR20230169427A (ko) 2023-12-15
NZ751983A (en) 2025-11-28
AU2022201291B2 (en) 2023-10-05
MY197491A (en) 2023-06-19
IL265010A (https=) 2019-04-30
AU2024200016B9 (en) 2025-08-07
KR20190075906A (ko) 2019-07-01
KR102609571B1 (ko) 2023-12-01
AU2017319306B2 (en) 2021-12-02
AU2022201291A1 (en) 2022-03-17
CN119979612A (zh) 2025-05-13
MX2019002321A (es) 2019-10-21
US20220089660A1 (en) 2022-03-24
SG10202102061SA (en) 2021-04-29
US20190241628A1 (en) 2019-08-08
RU2019109021A3 (https=) 2021-02-02
AU2025248765A1 (en) 2025-10-30
AU2017319306A1 (en) 2019-04-11
IL265010B2 (en) 2024-06-01
KR102877327B1 (ko) 2025-10-27
CN110023327A (zh) 2019-07-16

Similar Documents

Publication Publication Date Title
AU2021204416B2 (en) A modified mGluR6 promoter and methods of use
US12234267B2 (en) Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
ES2741502T3 (es) Cápside de AAV8 modificada para la transferencia génica para terapias de retina
US20220088222A1 (en) Compositions and methods for the treatment of degenerative ocular diseases
BR122024010814A2 (pt) Vetor de expressão de vírus adeno-associado (aav) ou de vírus adenoassociado recombinante (raav), composição farmacêutica, usos dos mesmos, e método para alterar a condutividade de uma membrana
WO2023285987A1 (en) Retgc gene therapy
WO2025137649A1 (en) Method of enhancing viral mediated gene delivery

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Z-H.Pan

Inventor after: T. Gangawala

Inventor after: Q.Lu

Inventor after: G. Abrams

Inventor before: Z-H.Pan